Navigation Links
Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Date:6/1/2009

gnancies, either as a stand-alone treatment or when used in combination with other therapies. These diseases are not curable presently, and eventually patients with these diseases show diminished response to current therapies. These patients and their physicians need more effective therapies with new mechanisms of action that address new targets. We look forward to presenting additional data on our expanding clinical experience with TRU-016 as it is accrued."

TRU-016 is a humanized, SMIP protein therapeutic that targets the CD37 antigen and has shown potent anti-tumor activity in pre-clinical studies. Trubion initiated a Phase 1 / 2 clinical trial of TRU-016 in March 2008. The open-label clinical trial has two components: a Phase 1 dose escalation study designed to evaluate the safety, tolerability and pharmacokinetics of TRU-016, and a Phase 2 expansion cohort designed to further evaluate safety and estimate clinical activity of TRU-016 in patients with previously treated CLL or SLL.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase

1 / 2
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
4. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
5. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
6. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
7. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
8. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
9. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... June 29, 2015 , ... World ... Fresh Plus Diaper, a baby invention that makes parenthood less tiring without sacrificing ... reach a market value of USD 52.2 billion in 2017," says Scott Cooper, ...
(Date:6/29/2015)... ... June 29, 2015 , ... People across the country give their coworkers and families gifts ... our culture. , But, how often do coworkers donate “life” to the husband of ... one. , “Dawna (Wright-Thompson) told me her husband was on a donor list,” ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... With Urgent ... announces a partnership with the American Board of Urgent Care Medicine and the Medical ... Category 1 Credit™ to Urgent Care physicians and health care professionals. , According to ...
(Date:6/29/2015)... Valley, CA (PRWEB) , ... June 29, 2015 , ... ... treatments designed to lift and tighten sagging skin. Ulthera is a special treatment that ... Instead, it uses ultrasound technology to gently stimulate collagen production. Ulthera is highly targeted ...
(Date:6/29/2015)... ... 2015 , ... New research released today at the National ... U.S. state and local governments have implemented Next Generation 9-1-1 (NG9-1-1) systems, and ... , “Mobile phones have surpassed land lines as the primary mode for calling ...
Breaking Medicine News(10 mins):Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 4
... LES ULIS, France, September 19 Following the,successful ... made it,possible to raise EUR7.6 million, Quantel signed ... company Wavelight AG to acquire,WaveLight Aesthetic GmbH, its ... agreement The acquisition price includes a EUR4.6 ...
... Sept. 19 If you,ve been experiencing watery,eyes and ... the,rise in the U.S., with an estimated 50 million ... to the tune of 3 billion,dollars a year, often ... say in-vitro blood tests, the latest generation of,allergy tests, ...
... with mice might lead to treatments for diseases such as ... U.S. researchers say they,ve successfully reprogrammed adult stem cells from ... cell types, including functional blood vessels, contractile cardiac tissue, and ... adult testes stem cells from humans, they may offer a ...
... Easily accessed and plentiful, adult stem cells found in a ... wide range of tissue types to help him fight disease ... cells. , That,s the promise of a breakthrough study in ... in New York City, who report their findings in the ...
... Americans will,have access to high-quality, evidence-based care for ... U.S. Senate. The,"Mental Health Parity Act of 2007" ... to provide parity with respect to all financial,requirements ... ) "AHIP applauds the Senate for ...
... Sept. 19 When Michael Murphy of,Seymour, Iowa, was ... the halftime of the September 15th Iowa vs. Iowa ... "Join the Ride, Iowa",raffle. The Iowa Farm Bureau donated ... and raffle (tickets were $10 each) to the American,Lung ...
Cached Medicine News:Health News:QUANTEL Finalizes the Acquisition of WaveLight Aesthetic GmbH 2Health News:Stem Cells From Testes Produce Wide Range of Tissue Types 2Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 2Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 3Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 4Health News:Renewable Fuel Chopper Raffle Nets $113,000 for American Lung Association Clean Air Choice Program 2
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: